Physician profile
Igor Kozak
NPI 1982982302
$7,817.06
in general payments reported to CMS, 2019-2025
11 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 79% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $6,475 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,475 · Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,475.00 |
| Food and Beverage | $2,342.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,785.05 | 2024 | |
| Alcon Vision LLC | $616.09 | 2024-2025 | Constellation, Unity |
| Genentech, INC. | $252.76 | 2024-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $225.23 | 2024-2025 | Izervay |
| Lkc Technologies, INC. | $222.66 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $147.48 | 2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $146.21 | 2025 | Acthar |
| Carl Zeiss Meditec USA, INC. | $145.00 | 2024 | Humphrey Hfa |
| Regeneron Healthcare Solutions, INC. | $123.26 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $120.18 | 2025 | Syfovre |
| Alimera Sciences, INC. | $33.14 | 2024 | Yutiq, Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Kozak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.